Skip to main content

Otezla Disease Interactions

There are 3 disease interactions with Otezla (apremilast).

Moderate

Apremilast (applies to Otezla) depression

Moderate Potential Hazard, Moderate plausibility.

Apremilast therapy has been associated with adverse reactions of depression. Therapy with apremilast should be administered cautiously in patients with a history of depression and/or suicidal thoughts or behavior. Patients, their caregivers, and families should be advised of the potential for emergence or worsening of depression, suicidal thoughts or other mood changes. The need for continued treatment with apremilast should be carefully weighed against the risks.

References

  1. "Product Information. Otezla (apremilast)." Celgene Corporation (2014):
Moderate

Apremilast (applies to Otezla) renal dysfunction

Moderate Potential Hazard, High plausibility.

Increased apremilast systemic exposure has been observed in patients with severe renal impairment (CrCl < 30 mL/min). Therapy with apremilast should be administered cautiously in these patients. Initial dosage titration and maintenance dosage should be reduced in accordance with the product package labeling.

References

  1. "Product Information. Otezla (apremilast)." Celgene Corporation (2014):
Moderate

Apremilast (applies to Otezla) weight loss

Moderate Potential Hazard, High plausibility. Applicable conditions: Malnourished, Anorexia/Feeding Problems, Weight Loss/Failure to Thrive

Apremilast therapy has been associated with weight loss. During controlled clinical trials, weight reduction between 5% to 10% of body weight was reported in 10% of patients treated with apremilast compared to 3.3% of those receiving placebo. Weight change should be monitored during apremilast therapy, particularly in patients suffering from anorexia, malnutrition, or excessive weight loss. Physicians should evaluate patients for any unexplained or clinically significant weight loss, and discontinuation of apremilast should be considered if appropriate.

References

  1. "Product Information. Otezla (apremilast)." Celgene Corporation (2014):

Otezla drug interactions

There are 86 drug interactions with Otezla (apremilast).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer